PATENT CLAIM ANALYSIS

Application Number: 16059715
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["546", "304000"]

Abstract:
The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.

Claim (Index 12):
A method of treating a disease selected from Alzheimer's disease (familial or sporadic), preclinical Alzheimer's disease, prodromal Alzheimer's disease, mild cognitive impairment, Down's syndrome and cerebral amyloid angiopathy, the method comprising administering a therapeutically effective amount of a compound according to anyone of  claims 1 - 10  to a patient in need thereof.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.4359
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14933301', '15524565', '15524479', '15524546', '15233463']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8267539768997765
- 35 USC 102 Novelty (BERT): 0.6030351075921719
- Combined Prediction Score: 0.804382089969016
- Mean Citation Score: 463.81169400000016
- Max Citation Score: 552.2594
- Similarity Product: 494.73296070431473

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test